Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Advanced Cell Technology, Inc. (“ACT” or the ”Company”; OTCBB: ACTC) a leader in the field of regenerative medicine, announced today its first quarter financial results for the period ended March 31, 2013. The Company reported a loss from operations of $(5.8) million compared to a loss from operations of $(5.4) million in the 2012 first quarter, primarily as a result of higher clinical trial expenses.
Help employers find you! Check out all the jobs and post your resume.
